Beyond LDL Cholesterol, a New Role for PCSK9

被引：50
|
作者：
Akram, Omar N. [1 ,2 ]
Bernier, Adeline [1 ,3 ]
Petrides, Francine [1 ]
Wong, Gida [1 ,4 ]
Lambert, Gilles [1 ,5 ]
机构：
[1] Heart Res Inst, Lipid Res Grp, Sydney, NSW, Australia
[2] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia
[3] Ecole Normale Super, F-75231 Paris, France
[4] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China
[5] Univ Nantes, Fac Med, Nantes, France
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2010年 / 30卷 / 07期
关键词：
atherosclerosis; lipoproteins; metabolism; DENSITY-LIPOPROTEIN-RECEPTOR; DOMINANT HYPERCHOLESTEROLEMIA; PLASMA-CHOLESTEROL; NONHUMAN-PRIMATES; MICE; PROPROTEIN-CONVERTASE-SUBTILISIN-KEXIN-TYPE-9;
D O I：
10.1161/ATVBAHA.110.209007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1279 / 1281
页数：3
相关论文
共 50 条
  • [1] PCSK9 MUTATIONS: EFFECTS BEYOND LDL CHOLESTEROL
    Zampoleri, V.
    Casula, M.
    Gazzotti, M.
    Baragetti, A.
    Pellegatta, F.
    Grigore, L.
    Catapano, A. L.
    ATHEROSCLEROSIS, 2019, 287 : E195 - E196
  • [2] Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
    Safarova, Maya
    Bimal, Tia
    Soffer, Daniel E.
    Hirsh, Benjamin
    Shapiro, Michael D.
    Mintz, Guy
    Cha, Agnes
    Gianos, Eugenia
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 19
  • [3] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [4] PCSK9 and atherosclerosis: beyond LDL
    Catapano, A. L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 28 - 28
  • [5] Potential of PCSK9 as a new target for the management of LDL cholesterol
    Mombelli, Guiliana
    Castelnuovo, Samuela
    Pavanello, Chiara
    RESEARCH REPORTS IN CLINICAL CARDIOLOGY, 2015, 6 : 73 - 86
  • [6] PCSK9 antibody reduces LDL cholesterol
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2012, 11 : 11 - 11
  • [7] Chasing LDL cholesterol to the bottom — PCSK9 in perspective
    Peter Libby
    Lale Tokgözoğlu
    Nature Cardiovascular Research, 2022, 1 : 554 - 561
  • [8] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    Stein, Evan A.
    Mellis, Scott
    Yancopoulos, George D.
    Stahl, Neil
    Logan, Douglas
    Smith, William B.
    Lisbon, Eleanor
    Gutierrez, Maria
    Webb, Cheryle
    Wu, Richard
    Du, Yunling
    Kranz, Therese
    Gasparino, Evelyn
    Swergold, Gary D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (12): : 1108 - 1118
  • [9] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    Banerjee, Yajnavalka
    Shah, Karna
    Al-Rasadi, Khalid
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (25): : 2425 - 2426
  • [10] Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
    Tavori, Hagai
    Melone, Michelle
    Rashid, Shirya
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (10) : 1137 - 1144
12345